Hypothesis
Rapamycin does not merely suppress mTOR; it imposes a temporal gate on JNK/AP-1 signaling that allows brief, protective pulses while preventing the transition to sustained SASP-driven inflammation. This kinetic checkpoint uncouples stress‑induced hormesis from inflammaging, explaining why lifespan extends without removing the underlying damage.
Mechanistic Basis
mTOR inhibition reduces phosphorylation of 4E-BP1 and S6K, lowering translational load and attenuating the feed‑forward loop where hyperactive translation fuels mitochondrial ROS production [1]. Reduced ROS limits the amplitude of mitochondrial damage‑activated JNK. Simultaneously, rapamycin enhances the expression of dual‑specificity phosphatases (DUSPs) that dephosphorylate JNK, shortening its active half‑life [2]. The result is a biphasic JNK profile: an early, transient peak that drives antioxidant genes (e.g., GCLC, SOD2) via AP‑1, followed by rapid return to baseline. Furthermore, rapamycin‑mediated reduction of mTORC1 activity diminishes S6K‑dependent phosphorylation of IRS‑1, alleviating insulin‑like feedback inhibition and preserving Akt‑mediated FOXO phosphorylation, which promotes nuclear translocation of FOXO transcription factors that cooperate with transient AP‑1 to upregulate DNA‑repair genes (e.g., GADD45A) without triggering SASP. In contrast, without rapamycin, persistent mTOR signaling sustains ROS, maintains JNK activity, and drives AP‑1‑dependent transcription of





























